London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...
AstraZeneca AZN0.05%increase; green up pointing triangle said it plans to pump $2 billion in new investment into the U.S., ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...
英国剑桥 - AstraZeneca PLC (LSE/STO/Nasdaq: AZN) 宣布在美国进行重大扩张,投资35亿美元用于扩大其研究和制造能力。这项投资计划将在2026年底前完成,预计将创造超过一千个高技能就业岗位,为经济增长做出贡献。 这家生物制药公司的投资将包括在马萨诸塞州剑桥市肯德尔广场建立一个新的最先进的研发中心,以及在马里兰州建立一个下一代生物制品制造设施。其他发展还包括在美国 ...